Information Provided By:
Fly News Breaks for November 5, 2018
ACRX
Nov 5, 2018 | 11:45 EDT
Cantor Fitzgerald analyst Brandon Folkes reiterated an Overweight rating on AcelRx and raised his price target to $9 from $8 after the approval of Dsuvia and the company's Q3 earnings results. Folkes believes the approval of Dsuvia remained discounted in the stock's price, given the opioid crisis, and now that an overhang has been removed, investors can look forward to the commercial potential of Dsuvia. Additionally, the analyst believes AcelRx's second product, Zalviso, has the potential to gain approval in the U.S. over the next 12 months.
News For ACRX From the Last 2 Days
There are no results for your query ACRX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.